OTCMKTS:CRTPF Cardiol Therapeutics (CRTPF) Stock Price, News & Analysis → READ THIS – If You Missed Out On The AI Boom (From Banyan Hill Publishing) (Ad) Free CRTPF Stock Alerts $2.14 -0.07 (-3.17%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$2.05▼$2.2450-Day Range$1.39▼$2.2152-Week Range$1.48▼$4.19Volume320,409 shsAverage Volume67,097 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartStock AnalysisChart Get Cardiol Therapeutics alerts: Email Address Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Cardiol Therapeutics Stock (OTCMKTS:CRTPF)Cardiol Therapeutics Inc. is a clinical-stage biotechnology company that focuses on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its product, CardiolRx, is a pharmaceutically produced extra strength oral cannabidiol formulation that is entering a Phase II/III outcomes study in hospitalized patients testing positive for the COVID-19 virus. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.Read More CRTPF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CRTPF Stock News HeadlinesFebruary 15, 2024 | finance.yahoo.comCardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of PericarditisOctober 12, 2023 | benzinga.comCardiol Therapeutics Fights Heart Inflammation With Novel FormulationsMay 12, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” September 13, 2023 | finance.yahoo.comCardiol Therapeutics Inc. (CRDL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?August 26, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc flat on Friday (CRDL)August 18, 2023 | theglobeandmail.comCardiol Therapeutics: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (CRDL)August 14, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc flat on Monday (CRDL)August 8, 2023 | finance.yahoo.comCardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital MarketMay 12, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 20, 2023 | theglobeandmail.comClosing Bell: Cardiol Therapeutics Inc up on Thursday (CRDL)November 11, 2022 | nasdaq.comHere's Why Cardiol Therapeutics Inc. (CRDL) Could be Great Choice for a Bottom FisherSeptember 24, 2022 | uk.finance.yahoo.comCardiol Therapeutics Inc. (CRDL)May 19, 2022 | stockhouse.comCardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of DirectorsJanuary 19, 2022 | finance.yahoo.comCardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory BoardJanuary 16, 2022 | nasdaq.comCardiol Therapeutics Inc - Class A Shares Close the Day 16.3% Higher - Daily WrapNovember 3, 2021 | reuters.comCardiol Therapeutics IncNovember 3, 2021 | marketwatch.comCardiol Therapeutics Shares Drop After Unit Offering PricesOctober 26, 2021 | nasdaq.comCardiol Therapeutics Inc. (CRDL) Could Find Support Soon, Here's Why You Should Buy the Stock NowOctober 18, 2021 | marketwatch.comCardiol Therapeutics Expanding LANCER Trial, Shares Trading HigherAugust 19, 2021 | finance.yahoo.comWhen Will Cardiol Therapeutics Inc. (TSE:CRDL) Turn A Profit?August 9, 2021 | msn.comBRIEF-Cardiol Therapeutics To Commence Trading On Nasdaq Under Symbol "CRDL"August 9, 2021 | proactiveinvestors.comCardiol Therapeutics receives final approval to list its common...August 9, 2021 | finance.yahoo.comCardiol Therapeutics to Commence Trading on NASDAQ Under the Symbol "CRDL"August 6, 2021 | barrons.comCardiol Therapeutics Inc.See More Headlines Receive CRTPF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cardiol Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:CRTPF CUSIPN/A CIKN/A Webwww.cardiolrx.com Phone(289) 910-0850FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDavid G. ElsleyPresident, Chief Executive Officer & DirectorBernard Ching-Bing LimChief Operating OfficerChristopher J. WaddickChief Financial Officer & SecretaryAnthony E. BoltonDirector of ResearchAndrew HamerChief Medical OfficerKey Competitors1933 IndustriesOTCMKTS:TGIFF4Cable TV InternationalOTCMKTS:CATV4Front VenturesOTCMKTS:FFNTFAB ScienceOTCMKTS:ABSCFAbacus Health ProductsOTCMKTS:ABAHFView All Competitors CRTPF Stock Analysis - Frequently Asked Questions How have CRTPF shares performed in 2024? Cardiol Therapeutics' stock was trading at $0.8432 on January 1st, 2024. Since then, CRTPF shares have increased by 153.8% and is now trading at $2.14. View the best growth stocks for 2024 here. How do I buy shares of Cardiol Therapeutics? Shares of CRTPF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:CRTPF) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 Media[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICMissed NVDA? Buy this AI stock NOWChaikin AnalyticsYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
